ADVANCED/METASTATIC BREAST CANCER

- Research Gaps

• Head-to-Head comparison for adjuvant Olaparib versus Capecitabine in TNBC received neoadjuvant treatment with residual disease.

• Pembrolizumab neoadjuvant exclusively versus neoadjuvant and adjuvant regarding survival benefit, toxicity including financial toxicity and quality of life.

•  This guideline will be updated whenever there is new evidence.

•  Randomized trials to determine the risks and benefits of brain screening in TNBC needed.